Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
976 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 976 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | Phase 2 | terminated | Mar 11, 2011 | Augusta University | Drug supply issues | Drug supply |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | Phase 1 | terminated | Nov 21, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd. | Will study new T-cell construct for the same indication | Other (stated, no rule matched) |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients… | Phase 2 | terminated | Apr 13, 2016 | Eben Rosenthal | Logistics | Other (stated, no rule matched) |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2018 | Hitendra Patel | FDA indicated the same study could not be conducted under multiple INDs | Other (stated, no rule matched) |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin…(LD-FOX4/HCC) | Phase 2 / Phase 3 | withdrawn | Aug 19, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for… | Phase 2 / Phase 3 | withdrawn | Aug 27, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy… | Phase 2 / Phase 3 | withdrawn | Oct 22, 2015 | Guangxi Medical University | not stated | Not stated |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | Phase 2 | withdrawn | Apr 18, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | Phase 2 | withdrawn | Feb 14, 2018 | M.D. Anderson Cancer Center | Incyte (supporter of the study) is no longer going to support the study. | Other (stated, no rule matched) |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and… | Phase 1 / Phase 2 | withdrawn | Apr 9, 2019 | Medical College of Wisconsin | Request to close per funding sponsor. Site not moving forward with trial. | Funding |
| NCT01498757 | Genome-wide Association Study | — | withdrawn | Dec 23, 2011 | Samsung Medical Center | Registration poor | Other (stated, no rule matched) |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type…(E-DIS) | Phase 2 | terminated | Nov 25, 2010 | Centre Oscar Lambret | not stated | Not stated |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing… | N/A | withdrawn | Oct 3, 2017 | University of Southern California | Accrual issue | Enrollment / accrual |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With… | N/A | terminated | Feb 7, 2011 | University of California, San Francisco | Off study clinical use of Y90 glass microspheres (TheraSphere) | Other (stated, no rule matched) |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | Phase 2 | withdrawn | Dec 14, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | Phase 2 | withdrawn | Dec 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | Phase 2 | withdrawn | Jan 14, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | Phase 3 | withdrawn | Nov 16, 2018 | Sun Yat-sen University | No paritcipants enrolled | Enrollment / accrual |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | Phase 2 | withdrawn | Dec 20, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven… | Phase 3 | withdrawn | Jan 3, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | Phase 2 | withdrawn | Nov 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | Phase 3 | terminated | Aug 30, 2012 | Rennes University Hospital | insufficient recruitment | Enrollment / accrual |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction… | Phase 2 | terminated | Apr 21, 2017 | Aduro Biotech, Inc. | Low enrollment and lack of clinical activity in other CRS-207 studies. | Enrollment / accrual |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary… | Phase 2 | terminated | Oct 31, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot… | Phase 1 | terminated | May 25, 2016 | University of Chicago | Closed early due to poor accrual. | Enrollment / accrual |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | Phase 2 | terminated | Jan 4, 2013 | Beth Israel Medical Center | not stated | Not stated |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Oct 17, 2014 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication | Other (stated, no rule matched) |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | — | terminated | Apr 25, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding due to difficulty with recruitment and participant retention. | Enrollment / accrual |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line… | Phase 2 | terminated | Dec 2, 2011 | University Health Network, Toronto | not stated | Not stated |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With… | N/A | terminated | Apr 22, 2016 | Fudan University | The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose… | Enrollment / accrual |
| NCT00256321 | Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma | Phase 2 | terminated | Nov 21, 2005 | University of California, Irvine | Closed due to poor accrual | Enrollment / accrual |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally… | Phase 4 | withdrawn | Oct 7, 2015 | Yonsei University | Investigator decided to stop the study because it was difficult to proceed with the study. | Investigator |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous… | Phase 4 | terminated | May 16, 2012 | Sun Yat-sen University | not stated | Not stated |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a… | Phase 2 / Phase 3 | terminated | Aug 19, 2014 | Sun Yat-sen University | protocol violation | Other (stated, no rule matched) |
| NCT00621036 | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | Phase 2 | withdrawn | Feb 22, 2008 | University of Texas Southwestern Medical Center | MyVax did not meet its primary endpoints | Other (stated, no rule matched) |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in… | Phase 2 | terminated | May 16, 2013 | Hellenic Cooperative Oncology Group | not stated | Not stated |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Phase 2 | terminated | Feb 1, 2016 | Washington University School of Medicine | Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice | Enrollment / accrual |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein… | Phase 1 / Phase 2 | terminated | Jan 27, 2017 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication. | Other (stated, no rule matched) |
| NCT03527784 | Prestoma-Trial for Parastomal Hernia Prevention | N/A | terminated | May 17, 2018 | University of Oulu | Parastomal Parietex withdrawn from market by the manufacturer. | Drug supply |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment… | Phase 2 | terminated | Jul 21, 2017 | National Cancer Institute (NCI) | Principal Investigator left the NIH. | Investigator |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | — | terminated | Jun 1, 2016 | The University of Texas Health Science Center, Houston | PI transferred to another institution and did not take this study with him. | Other (stated, no rule matched) |
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or… | Phase 2 | terminated | Sep 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in… | Phase 2 | withdrawn | Jul 18, 2017 | National Cancer Institute (NCI) | The study was never approved by CTEP neither was it ever activated | Other (stated, no rule matched) |
| NCT02599909 | Gut Microbiota in People With Hepatocellular Carcinoma (HCC) | — | withdrawn | Nov 9, 2015 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02204124 | Whipple Procedure: Standard of Care vs. Thunderbeat | N/A | terminated | Jul 30, 2014 | Washington University School of Medicine | Principal Investigator and Study Sponsor decided to terminate the study early | Investigator |
| NCT02967523 | Surefire Precision Infusion System Registry | — | terminated | Nov 18, 2016 | Surefire Medical, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 10, 2019source: clinicaltrials